Cost effectiveness of a pentavalent rotavirus vaccine in Oman

被引:7
|
作者
Al Awaidy, Salah Thabit [1 ,7 ]
Gebremeskel, Berhanu G. [2 ]
Al Obeidani, Idris [3 ]
Al Baqlani, Said [4 ]
Haddadin, Wisam [5 ]
O'Brien, Megan A. [6 ]
机构
[1] Minist Hlth, Off HE Hlth Affairs, Muscat, Oman
[2] Rutgers State Univ, Sch Publ Hlth, Piscataway, NJ USA
[3] Minist Hlth, DGHA, Dept Communicable Dis Surveillance & Control, Muscat, Oman
[4] Minist Hlth, DGHA, Cent Publ Hlth Lab, Muscat, Oman
[5] MSD EEMEA, Dubai, U Arab Emirates
[6] Merck & Co Inc, Global Hlth Outcomes, West Point, PA USA
[7] Minist Hlth, Off Undersecretary Hlth Affairs, Muscat 113, Oman
来源
BMC INFECTIOUS DISEASES | 2014年 / 14卷
关键词
Rotavirus; Vaccine; Cost effectiveness; Oman; Markov model; ACUTE GASTROENTERITIS; CHILDREN YOUNGER; INFECTION; MORTALITY; DISEASE; IMPACT; POPULATION; PROTECTION; PARENTS; BURDEN;
D O I
10.1186/1471-2334-14-334
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Rotavirus gastroenteritis (RGE) is the leading cause of diarrhea in young children in Oman, incurring substantial healthcare and economic burden. We propose to formally assess the potential cost effectiveness of implementing universal vaccination with a pentavalent rotavirus vaccine (RV5) on reducing the health care burden and costs associated with rotavirus gastroenteritis (RGE) in Oman Methods: A Markov model was used to compare two birth cohorts, including children who were administered the RV5 vaccination versus those who were not, in a hypothetical group of 65,500 children followed for their first 5 years of life in Oman. The efficacy of the vaccine in reducing RGE-related hospitalizations, emergency department (ED) and office visits, and days of parental work loss for children receiving the vaccine was based on the results of the Rotavirus Efficacy and Safety Trial (REST). The outcome of interest was cost per quality-adjusted life year (QALY) gained from health care system and societal perspectives. Results: A universal RV5 vaccination program is projected to reduce, hospitalizations, ED visits, outpatient visits and parental work days lost due to rotavirus infections by 89%, 80%, 67% and 74%, respectively. In the absence of RV5 vaccination, RGE-related societal costs are projected to be 2,023,038 Omani Rial (OMR) (5,259,899 United States dollars [USD]), including 1,338,977 OMR (3,481,340 USD) in direct medical costs. However, with the introduction of RV5, direct medical costs are projected to be 216,646 OMR (563,280 USD). Costs per QALY saved would be 1,140 OMR (2,964 USD) from the health care payer perspective. An RV5 vaccination program would be considered cost saving, from the societal perspective. Conclusions: Universal RV5 vaccination in Oman is likely to significantly reduce the health care burden and costs associated with rotavirus gastroenteritis and may be cost-effective from the payer perspective and cost saving from the societal perspective.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Cost effectiveness of a pentavalent rotavirus vaccine in Oman
    Salah Thabit Al Awaidy
    Berhanu G Gebremeskel
    Idris Al Obeidani
    Said Al Baqlani
    Wisam Haddadin
    Megan A O’Brien
    [J]. BMC Infectious Diseases, 14
  • [2] Effectiveness of Monovalent and Pentavalent Rotavirus Vaccine
    Cortese, Margaret M.
    Immergluck, Lilly Cheng
    Held, Melissa
    Jain, Shabnam
    Chan, Trisha
    Grizas, Alexandra P.
    Khizer, Saadia
    Barrett, Carol
    Quaye, Osbourne
    Mijatovic-Rustempasic, Slavica
    Gautam, Rashi
    Bowen, Michael D.
    Moore, Jessica
    Tate, Jacqueline E.
    Parashar, Umesh D.
    Vazquez, Marietta
    [J]. PEDIATRICS, 2013, 132 (01) : E25 - E33
  • [3] COST EFFECTIVENESS OF PENTAVALENT ROTAVIRUS VACCINE (RV5) IN SLOVENIA
    Gebremeskel, B. G.
    Pokorn, M.
    Zakotnik, B.
    O'Brien, M. A.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A509 - A509
  • [4] Effectiveness of Pentavalent Rotavirus Vaccine Against Severe Disease
    Staat, Mary Allen
    Payne, Daniel C.
    Donauer, Stephanie
    Weinberg, Geoffrey A.
    Edwards, Kathryn M.
    Szilagyi, Peter G.
    Griffin, Marie R.
    Hall, Caroline B.
    Curns, Aaron T.
    Gentsch, Jon R.
    Salisbury, Shelia
    Fairbrother, Gerry
    Parashar, Umesh D.
    [J]. PEDIATRICS, 2011, 128 (02) : E267 - E275
  • [5] Cost Effectiveness of both (Monovalent and Pentavalent) Rotavirus Vaccines
    Hacimustafaoglu, Mustafa
    Celebi, Solmaz
    Akin, Levent
    Agin, Mehmet
    Sevencan, Funda
    [J]. JOURNAL OF PEDIATRIC INFECTION, 2013, 7 (01): : 13 - 20
  • [6] Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana
    Abbott, Collette
    Tiede, Benjamin
    Armah, George
    Mahmoud, Adel
    [J]. VACCINE, 2012, 30 (15) : 2582 - 2587
  • [7] Effectiveness of the Pentavalent Rotavirus Vaccine in Preventing Gastroenteritis in the United States
    Wang, Florence T.
    Mast, T. Christopher
    Glass, Roberta J.
    Loughlin, Jeanne
    Seeger, John D.
    [J]. PEDIATRICS, 2010, 125 (02) : E208 - E213
  • [8] The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales
    Atkins, Katherine E.
    Shim, Eunha
    Carroll, Stuart
    Quilici, Sibilia
    Galvani, Alison P.
    [J]. VACCINE, 2012, 30 (48) : 6766 - 6776
  • [9] Effectiveness of Pentavalent Rotavirus Vaccine Under Conditions of Routine Use in Rwanda
    Tate, Jacqueline E.
    Ngabo, Fidele
    Donnen, Philippe
    Gatera, Maurice
    Uwimana, Jeannine
    Rugambwa, Celse
    Mwenda, Jason M.
    Parashar, Umesh D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2016, 62 : S208 - S212
  • [10] Effectiveness of Pentavalent Rotavirus Vaccine in a Large Urban Population in the United States
    Boom, Julie A.
    Tate, Jacqueline E.
    Sahni, Leila C.
    Rench, Marcia A.
    Hull, Jennifer J.
    Gentsch, Jon R.
    Patel, Manish M.
    Baker, Carol J.
    Parashar, Umesh D.
    [J]. PEDIATRICS, 2010, 125 (02) : E199 - E207